calendar
2 catalysts · 4,970 phase readout · 2,331 8k filing · 283 earnings · 277 pdufa · 115 phase 2 completion · 53 phase 1 completion
next 91 dayslessmore
MonWedFri
2 catalysts · 4,970 phase readout · 2,331 8k filing · 283 earnings · 277 pdufa · 115 phase 2 completion · 53 phase 1 completion
Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer